febit to Receive Funding from a Federal Grant Awarded in the German Excellence Cluster Contest
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
As early as mid-February, febit will start setting up the Biomarker Discovery Center Heidelberg, one of the projects recently awarded funding from the Excellence Cluster Initiative of the German Federal Ministry of Education and Research (BMBF).
Together, the projects of the companies involved in the Biotech Excellence Cluster Rhine-Neckar were granted a total of 40 million Euros for the development of innovative drugs, diagnostics and technologies in cellular and molecular biology.
febit convinced the jury with two projects: in mid-February febit will start combining microarray technology and high-throughput sequencing (Next Generation Sequencing) to create powerful and cost-effective procedures for the development and validation of novel biomarkers.
The second project aims at the determination of novel tumor markers. Collaborating with the German Cancer Research Center (DKFZ), febit will conduct studies directed at the identification of markers for various cancer types and develop these into standardized diagnostic assays in the near future.
“We are pleased that the grant gives us the opportunity to initiate these scientifically advanced projects. febit´s highly versatile and equally automatable technology is ideally suited for the use in diagnostics requiring individual investigations with standardized procedures,“ explains febit CSO Peer Stahler.
This particular technology will be able to identify candidate markers which are then statistically analyzed by a package of software algorithms. A novel DNA enrichment technology will capture samples for high-throughput sequencing machines, thus allowing rapid and efficient characterization of genes involved in tumor formation.
Together, the projects of the companies involved in the Biotech Excellence Cluster Rhine-Neckar were granted a total of 40 million Euros for the development of innovative drugs, diagnostics and technologies in cellular and molecular biology.
febit convinced the jury with two projects: in mid-February febit will start combining microarray technology and high-throughput sequencing (Next Generation Sequencing) to create powerful and cost-effective procedures for the development and validation of novel biomarkers.
The second project aims at the determination of novel tumor markers. Collaborating with the German Cancer Research Center (DKFZ), febit will conduct studies directed at the identification of markers for various cancer types and develop these into standardized diagnostic assays in the near future.
“We are pleased that the grant gives us the opportunity to initiate these scientifically advanced projects. febit´s highly versatile and equally automatable technology is ideally suited for the use in diagnostics requiring individual investigations with standardized procedures,“ explains febit CSO Peer Stahler.
This particular technology will be able to identify candidate markers which are then statistically analyzed by a package of software algorithms. A novel DNA enrichment technology will capture samples for high-throughput sequencing machines, thus allowing rapid and efficient characterization of genes involved in tumor formation.
